Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Financials
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  08:38:59 2023-03-22 am EDT
10843.00 GBX   -0.56%
08:25aAstrazeneca : Marked up version of proposed new Articles to be considered by shareholders at the Annual General Meeting on 27 April 2023
PU
08:25aAstrazeneca : Publication of proposed new Articles to be considered by shareholders at the Annual General Meeting on 27 April 2023
PU
08:25aAstrazeneca : Proxy Form for 2023 AGM
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization1 131 461181 878210 243206 072--
Enterprise Value (EV)1 143 328206 261233 166226 562222 061215 797
P/E ratio 41,0x1 468x64,3x29,2x22,0x19,4x
Yield 2,80%2,44%2,14%2,28%2,36%2,45%
Capitalization / Revenue 4,94x4,86x4,74x4,49x4,07x3,80x
EV / Revenue 5,38x5,51x5,26x4,93x4,39x3,98x
EV / EBITDA 17,2x27,2x25,2x14,5x11,9x10,5x
Enterprise Value (EV) / FCF 37,3x42,3x26,7x28,7x20,5x17,2x
FCF Yield 2,68%2,36%3,74%3,49%4,87%5,82%
Price to Book 8,41x4,24x5,67x5,21x4,59x4,01x
Nbr of stocks (in thousands) 1 312 6601 549 1591 549 5281 549 833--
Reference price (USD) 100117136133133133
Announcement Date 02/11/202102/10/202202/09/2023---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales1 26 61737 41744 35145 93850 57354 208
EBITDA1 8 3117 5869 23715 66118 69220 532
Operating profit (EBIT)1 7 3409 92813 35014 49217 47719 922
Operating Margin 27,6%26,5%30,1%31,5%34,6%36,8%
Pre-Tax Profit (EBT)1 3 916-2652 5019 09012 62614 902
Net income1 3 1961123 2887 3239 94511 347
Net margin 12,0%0,30%7,41%15,9%19,7%20,9%
EPS2 2,440,082,114,556,056,84
Free Cash Flow1 3 8384 8728 7177 89910 82512 552
FCF margin 14,4%13,0%19,7%17,2%21,4%23,2%
FCF Conversion 46,2%64,2%94,4%50,4%57,9%61,1%
Dividend per Share2 2,802,872,903,033,133,26
Announcement Date 02/11/202102/10/202202/09/2023---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales1 10 77110 98211 20710 90911 11111 481
EBITDA 1 8962 5792 574---
Operating profit (EBIT)1 3 3653 4132 6103 5073 7013 980
Operating Margin 31,2%31,1%23,3%32,1%33,3%34,7%
Pre-Tax Profit (EBT) 247922778---
Net income1 3601 6409011 8131 9412 115
Net margin 3,34%14,9%8,04%16,6%17,5%18,4%
EPS2 0,231,050,581,161,241,36
Dividend per Share2 0,93-1,97---
Announcement Date 07/29/202211/10/202202/09/2023---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt1 11 86724 38322 92320 49015 9889 724
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,43x3,21x2,48x1,31x0,86x0,47x
Free Cash Flow1 3 8384 8728 7177 89910 82512 552
ROE (Net Profit / Equities) 36,7%27,5%27,2%29,1%31,3%30,6%
Shareholders' equity1 8 70440712 07425 14831 75737 116
ROA (Net Profit / Asset) 4,99%8,77%3,26%9,31%11,2%11,8%
Assets1 64 0531 277100 92478 65789 15895 964
Book Value Per Share2 11,927,723,925,529,033,1
Cash Flow per Share2 3,664,186,296,877,929,18
Capex1 9611 0911 0911 6851 9032 028
Capex / Sales 3,61%2,92%2,46%3,67%3,76%3,74%
Announcement Date 02/11/202102/10/202202/09/2023---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
Key data
Capitalization (GBP) 168 993 843 422
Capitalization (USD) 206 072 461 402
Net sales (USD) 44 351 000 000
Number of employees 83 500
Sales / Employee (USD) 531 150
Free-Float 96,4%
Free-Float capitalization (GBP) 162 976 741 114
Free-Float capitalization (USD) 198 735 158 113
Avg. Exchange 20 sessions (USD) 15 455 285 480
Average Daily Capital Traded 9,15%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer